Skip to main content

Peer Review reports

From: Bifunctional anti-PD-L1/TGF-βRII agent SHR-1701 in advanced solid tumors: a dose-escalation, dose-expansion, and clinical-expansion phase 1 trial

Original Submission
9 Jun 2022 Submitted Original manuscript
19 Jul 2022 Reviewed Reviewer Report
1 Aug 2022 Reviewed Reviewer Report
29 Aug 2022 Author responded Author comments - Dan Liu
Resubmission - Version 2
29 Aug 2022 Submitted Manuscript version 2
30 Aug 2022 Reviewed Reviewer Report
28 Sep 2022 Author responded Author comments - Dan Liu
Resubmission - Version 3
28 Sep 2022 Submitted Manuscript version 3
Publishing
12 Oct 2022 Editorially accepted
25 Oct 2022 Article published 10.1186/s12916-022-02605-9

You can find further information about peer review here.

Back to article page